NCT07112937 The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study
| NCT ID | NCT07112937 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic |
| Condition | Rectal Cancer Patients |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-05-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-05-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prospective study will focus on patients undergoing multimodal treatment for rectal cancer. The main objective of the study will be to monitor changes in circulating tumor cells (CTCs) in the peripheral blood of patients during multimodal treatment. For each patient enrolled in the study, peripheral blood samples will be collected at specified time intervals to determine the presence and quantity of CTCs. The CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.
Eligibility Criteria
Inclusion Criteria: rectal cancer - Exclusion Criteria: no other cancer \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07112937 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07112937 currently recruiting?
Yes, NCT07112937 is actively recruiting participants. Contact the research team at josef.srovnal@upol.cz for enrollment information.
Where is the NCT07112937 trial being conducted?
This trial is being conducted at Ostrava, Czechia.
Who is sponsoring the NCT07112937 clinical trial?
NCT07112937 is sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.